Man cycles 500km from North Yorkshire to London for Blood Cancer UK
James Badger recently cycled 500km from North Yorkshire to London in memory of his late wife Philippa.
He was joined for the feat by director of York-based dust extraction firm APS, Adrian Ogden.
Mr Badger's challenge saw him cycle 500km from St James' Church, in Birstwith, to St James's, in London, on a 42-year-old tandem bike, with the bike's age being the same as that of his wife when she sadly passed away.
The feat took place across the three days leading up to the London Marathon (Sunday, April 27) - in which Mr Badger also took part.
Mr Badger's wife was diagnosed with blood cancer in 2022, and died two days later while being treated with chemotherapy at St James's University Hospital in Leeds.
The Tandem to the Thames challenge is in aid of Blood Cancer UK, raising funds for a York University research project into Acute Myeloid Leukaemia treatments.
To donate, please visit justgiving.com/page/philippabadger2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
TN trans care ban: AG said defending case to SCOTUS, expected to rule soon, was God's will
DALLAS — Potentially days before the U.S. Supreme Court rules in a landmark case on a ban on transgender youth receiving certain medical care, Tennessee's attorney general told a room of Southern Baptists he believes it was God's providence that he argued before the land's highest court. "I'm in the middle of things that are so much bigger than I have any business being in the middle of. But I'm there for a reason," Tennessee Attorney General Jonathan Skrmetti said during a June 10 panel discussion at the Kay Bailey Hutchison Convention Center in Dallas. 'So, I just try to remember it's not about me and that God puts his people where he needs them, where he wants them." Skrmetti's office is defending Tennessee's ban on gender transition treatments for transgender minors, which a Nashville family with a transgender teenager is challenging. The Supreme Court may decide on the case as early as June 12, and a majority of justices have signaled a friendly disposition toward upholding Tennessee's law that took effect in June 2023. The June 10 event was organized by the Nashville-based SBC's public policy arm, the Ethics & Religious Liberty Commission. Skrmetti and another panelist, Alliance Defending Freedom senior vice president Ryan Bangert, said the case is about science and the degree to which courts can decide public policy. But Skrmetti and Bangert, whose law firm is helping represent Tennessee in U.S. v. Skrmetti, acknowledged faith is another key component of this story and will potentially be a resounding victory for conservative Christians. More: Meet the Tennessee family behind the US Supreme Court's major transgender health care case 'I would be ready to have good conversations with your congregants, good conversations with your fellow church members about what this case means not just from a legal perspective. But from a broader cultural perspective,' Bangert said at the June 10 panel. 'I would be ready to have that conversation: 'God willing, the law has been upheld. What do we do know?'' Alliance Defending Freedom has been a decisive force in several recent U.S. Supreme Court cases that have reversed precedent in favor of conservative Christian ideals. Examples include Dobbs v. Jackson Women's Health Organization that overturned Roe v. Wade, Kennedy v. Bremerton dealing with public prayer on a high school sports field, and 303 Creative v. Elenis about a Christian web designer's refusal to work with same-sex couples. The Southern Baptist Convention is the nation's largest Protestant denomination. The Ethics & Religious Liberty Commission stated its opposition to transition treatment for transgender people in resolutions at past SBC annual meetings and has been a vocal proponent of bans in Tennessee and other states. Bangert said at the June 10 panel there are 26 states with bans like Tennessee's and the decision in U.S. v. Skrmetti could affect those other laws. The ERLC filed an amicus brief in U.S. v. Skrmetti, for which the SBC-affiliated agency hired a Southern Baptist lawyer to carefully and forcefully assert the Southern Baptists' position on the issue. Skrmetti praised the ERLC's amicus brief during the June 10 panel, saying it provided a theological rationale for Tennessee's law. Skrmetti's office cannot make that theological argument in its defense before the Supreme Court because an establishment clause requires the state to approach the case from a religiously neutral perspective. Skrmetti, who attends a Church of Christ congregation in Nashville, said at the June 10 panel in his capacity at Tennessee's attorney general that his religion is not a factor in how he approaches the case. But personally, he told the crowd of Southern Baptists in Dallas that the outcome will be meaningful as a person of faith. 'Pray for my team that all of us that if we win, win gracefully in a way that reinforces both shining God's light into the world,' Skrmetti said. Liam Adams covers religion for The Tennessean, part of the USA TODAY Network. Reach him at ladams@ or on social media @liamsadams. This article originally appeared on Nashville Tennessean: Skrmetti cites God's will to his role in SCOTUS trans care case at SBC
Yahoo
28 minutes ago
- Yahoo
Enhance.MD Launches Nationwide Telehealth Expansion to Support Men's Hormonal Health and Medically Supervised Weight Loss
Virtual platform now offers licensed physician care for testosterone therapy, GLP-1 weight loss support, and men's wellness programs across all 50 U.S. states San Diego, June 10, 2025 (GLOBE NEWSWIRE) -- a U.S.-based telehealth provider specializing in men's hormonal optimization and metabolic wellness, has officially expanded its clinical care services nationwide. This expansion supports a growing number of men seeking personalized healthcare solutions for low testosterone, weight challenges, and performance-related health issues—all from the convenience of their own home. Through its secure platform, connects patients to licensed U.S. physicians who evaluate medical history, review lab work, and prescribe clinically appropriate treatment programs. The company's services now reach patients in all 50 states, including those in remote or underserved areas where access to specialized care may be limited. 'Our mission is to make medically supervised hormone therapy and weight loss care more accessible for men everywhere,' said a spokesperson for 'This nationwide expansion reflects our commitment to safe, evidence-based telemedicine that empowers patients to take charge of their long-term health.' virtual platform is designed for ease of use, featuring: Fast, secure medical intake and scheduling Lab partnerships for at-home or local diagnostic testing Ongoing provider monitoring and patient support HIPAA-compliant communication channels Nationwide medication delivery where legally permitted All care is provided by board-certified physicians and licensed healthcare professionals who follow strict clinical guidelines. Treatment options may include testosterone replacement therapy (TRT), GLP-1-based metabolic weight programs, and supportive interventions for men's health, always following a personalized and physician-reviewed protocol. With recent updates to its website and mobile user interface, has also improved patient onboarding, reduced consultation wait times, and expanded clinical support availability. About is a telehealth company focused on optimizing men's health through medical evaluation, diagnostic testing, and customized treatment plans. The company specializes in testosterone therapy, weight management, and performance-focused wellness protocols—delivered entirely online through licensed U.S. providers. By combining technology with medical oversight, empowers men to pursue health goals with professional guidance and national reach. Contact: AM – 8:00 PM EDT Monday – Friday9:00 AM – 5:00 PM EDT Saturday – Sunday16776 Bernardo Center Dr. Suite 203, San Diego, CA 92128https:// SOURCE: Disclaimer This press release is for informational purposes only. provides healthcare services under licensed clinical supervision in compliance with state and federal regulations. No part of this release should be interpreted as medical advice or a substitute for an in-person doctor consultation. Treatment eligibility, outcomes, and availability may vary based on individual patient circumstances and state-specific regulations. CONTACT: 1-888-299-5088 support@ 8:00 AM – 8:00 PM EDT Monday – Friday 9:00 AM – 5:00 PM EDT Saturday – SundayError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
41 minutes ago
- Yahoo
Caris Life Sciences files for $424M IPO
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Precision medicine company Caris Life Sciences said Monday it expects to raise as much as $423.5 million in an initial public offering. The Irving, Texas-based company plans to list its common stock on the Nasdaq market under the symbol 'CAI,' offering 23.5 million shares at $16 to $18 each. Primarily focused on cancer, Caris' molecular profiling tools use artificial intelligence and machine learning algorithms to analyze disease for early detection, diagnosis, monitoring, therapy selection and drug development. Caris saw year-over-year revenue growth of about 50%, to $120.9 million, in the first quarter of 2025, driven primarily by its molecular profiling services, according to a securities filing. The company received Food and Drug Administration approval for its companion diagnostic test MI Cancer Seek in November. The test identifies cancer patients who may benefit from targeted treatments. Founded in 2008, Caris has identified about 915,000 unique pathogenic mutations to date, of which only about 17,000 were previously known, the company said in its filing. 'We can now identify a person's circulating pathogenic mutations and enable the design of a customized individualized therapy to that specific set of mutations,' David Dean Halbert, Caris founder and CEO, said in the filing. 'We believe this is going to create the opportunity for physicians to use our solutions to effectively prevent various chronic diseases before they ever get started at the earliest of stages.' In April, when the company closed a private funding round worth $168 million, it said it had raised a total of $1.86 billion in capital since 2018. Caris is among a handful of companies exploring a public offering in a medtech IPO market that's showing signs of emerging from a slump. Medical products supplier Medline has said it could go public, and Medtronic plans to separate its diabetes business into a standalone company, potentially through an IPO. Recommended Reading The medtech IPO window is finally open. Or is it? Sign in to access your portfolio
